Balyasny Asset Management
PACB icon

Balyasny Asset Management’s Pacific Biosciences PACB Stock Holding History

Balyasny Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,000
Closed -$111K – 3160
2022
Q2 		$111K Buy
+25,000
New +$152K ﹤0.01% 2269
2016
Q4 		– Sell
-169,023
Closed -$46K – 1449
2016
Q3 		$46K Buy
+169,023
New +$1.41M ﹤0.01% 950

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's PACB Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Pacific Biosciences (PACB) in Q1 2026: 260,538 shares worth $344K. The stake represents ﹤0.01% of the portfolio and ranks #2511 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in PACB as recently as Q1 2024.

Balyasny Asset Management first reported a position in PACB in Q4 2015 and has held it in 16 quarters since. The position peaked at $10.4M in Q1 2019. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Balyasny Asset Management held 260,538 shares of Pacific Biosciences worth $344K as of Q1 2026.
  • Pacific Biosciences was a new Balyasny Asset Management position in Q1 2026.
  • Pacific Biosciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2511 holding.
  • Balyasny Asset Management first reported a position in Pacific Biosciences in Q4 2015 and has held it in 16 quarters since.
  • Balyasny Asset Management's Pacific Biosciences position peaked at $10.4M in Q1 2019.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.